Inside ASCO 2025
Last Updated: June 18, 2025
What does the future of cancer care look like? From replacing IV chemo with oral agents to game-changing advances in bispecific and trispecific therapies, this special bonus episode dives deep into the most exciting—and practice-changing—developments from the 2025 ASCO Annual Meeting.
NCODA’s Kelly Brunk, PharmD, BCOP, returns from ASCO energized and ready to share his top takeaways in a candid conversation about where oncology is headed. Whether you’re a clinician, pharmacist, or anyone in the cancer care ecosystem, this episode is packed with insight you don’t want to miss.
Bonus: Kelly also shares updates on NCODA’s new Immunotherapy Hub and offers a forward-looking take on where the field is headed.
“The rate of change in oncology care is accelerating—and it’s time for practices to be ready, not reactive.” — Kelly Brunk
Inside the Episode:
- How oral therapies are reshaping breast cancer treatment
- The evolving role of bispecifics, trispecifics, and antibody-drug conjugates
- Practical considerations for implementation: protocols, access, and infrastructure
- The importance of quality of life in treatment decisions
- Early use of immune checkpoint inhibitors in multiple disease states
- How AI and equity are shaping the next decade of oncology
Listen now and explore what these developments mean for clinical practice—and for the patients at the center of it all.
Resources mentioned:
- NCODA’s Immunotherapy Hub – A central resource offering clinical tools, SOP examples, and support for implementing therapies like bispecifics and antibody-drug conjugates.
- Questions or looking to connect? Email the NCODA Clinical Team at clinical@ncoda.org